Eckardt A, Wegener G, Karstens J H
Klinik für Mund-, Kiefer- und Gesichtschirurgie, Medizinische Hochschule Hannover, Hannover, Germany.
Mund Kiefer Gesichtschir. 2006 Jan;10(1):30-6. doi: 10.1007/s10006-005-0659-8.
The purpose of simultaneous chemoradiotherapy is to increase local tumor control and to decrease the incidence of distant metastases. Platinum-based chemotherapy regimens are widely accepted as standard treatment in advanced head and neck cancer. Due to their remarkable activity as well as radiosensitizing effects, taxanes play in increasing role in multimodality treatment concepts of solid tumors.
Since 1989 a total of 85 patients with advanced squamous cell carcinoma of the oral cavity and oropharynx were recruited to participate in two different prospective clinical trials of preoperative chemoradiation. Both treatment concepts (study A: cisplatin 12.5 mg/m(2) plus radiation 36 Gy vs study B: Taxol 40 mg/m(2)/carboplatin AUC 1.5 plus radiation 40 Gy) were compared and further statistical analysis including descriptive analysis as well as univariate and multivariate analysis was performed.
At the time of the analysis a total of 47 patients (55.3%) were alive, 38 patients (44.7%) died from tumor-related causes. The overall survival for both patient groups at 5 years was 45.1% (study A) and 84.9% (study B) and after 10 years 32.4% for study group A. A comparative analysis of both groups revealed a highly significant survival benefit at 4 years for study B (p=0.0015). In various calculation models of the multivariate analysis the regimen containing Taxol/carboplatin (study B) was superior to the cisplatin regimen (study A).
Based on a retrospective analysis of two different concepts of preoperative chemoradiation and supported by recent data from the literature it is justified to conclude that taxane-based combination regimens are more effective compared to cisplatin-based regimens.
同步放化疗的目的是提高局部肿瘤控制率并降低远处转移的发生率。铂类化疗方案被广泛接受为晚期头颈癌的标准治疗方法。由于紫杉烷类药物具有显著的活性以及放射增敏作用,它们在实体瘤的多模式治疗理念中发挥着越来越重要的作用。
自1989年以来,共有85例口腔和口咽晚期鳞状细胞癌患者被招募参加两项不同的术前放化疗前瞻性临床试验。比较了两种治疗方案(研究A:顺铂12.5mg/m²加放疗36Gy,研究B:紫杉醇40mg/m²/卡铂AUC 1.5加放疗40Gy),并进行了进一步的统计分析,包括描述性分析以及单因素和多因素分析。
在分析时,共有47例患者(55.3%)存活,38例患者(44.7%)死于肿瘤相关原因。两组患者的5年总生存率分别为45.1%(研究A)和84.9%(研究B),研究A组10年后为32.4%。两组的比较分析显示,研究B组在4年时具有高度显著的生存获益(p = 0.0015)。在多因素分析的各种计算模型中,含紫杉醇/卡铂的方案(研究B)优于顺铂方案(研究A)。
基于对两种不同术前放化疗概念的回顾性分析,并得到近期文献数据的支持,有理由得出结论,与基于顺铂的方案相比,基于紫杉烷的联合方案更有效。